Call Toll Free
866-321-6558
Home|About Prometa|About Substance Dependence|Family & Friends|Healthcare Professionals|Contact Us Now
withdrawal
 
 
Prometa Treatment Studies  
Clinical Study of the PROMETA Treatment Program for Alcohol Dependence at the Medical University of South Carolina (MUSC), Charleston, SC
Raymond F. Anton, MD; Hugh Myrick, MD;  Alicia M. Baros, PhD; Patricia K. Latham, PhD; Patrick K. Randall, PhD; Tara M. Wright, MD;  Scott H. Stewart, MD; Randy Waid, PhD; and Robert Malcolm, MD
> 60-subject, double-blind, placebo-controlled study
> Percent days abstinent and time to first heavy drinking day as primary endpoints
Study published in the Journal of Clinical Psychopharmacology, August 2009; 29(4):334-342.
 
   
Clinical Study of the PROMETA Treatment Program for Methamphetamine Dependent Subjects at Research Across America, Dallas, TX
Harold C. Urschel III, MD, MMA; Larry L. Hanselka, PhD; Michael Baron, PhD
> 135-subject, double-blind, placebo-controlled study
> Craving, drug use, and the correlation between the two as endpoints
Study published in the Journal of Psychopharmacology, November 25, 2009.
 
   
An Open-label Study on the Safety and Clinical Effectiveness of the PROMETA Treatment Program in Treating Methamphetamine Dependence at Research Across America, Dallas, TX
Harold C. Urschel III, MD, MMA;  Larry L. Hanselka, PhD; Irina Gromov, MD, PhD; Lenae White, MD; Michael Baron, PhD
> 50-subject open-label study
> Craving, number of days abstinent as endpoints
Study published in Mayo Clinic Proceedings, October 2007;82(10):1170-1178.
 
   
Clinical study of the PROMETA Treatment Program for alcohol dependence at Institute of Addiction Medicine, Philadelphia, PA
Joseph R. Volpicelli, M.D.; PhD, Emily Loscalzo, MS; Jenny Starosta, PhD; and Domenick Braccia, DO
> 120-subject, randomized, double-blind, placebo-controlled study
> Craving and percent drinking days as endpoints
Study completed and submitted for publication.
 
   
 
 
FAQ About Prometa
Contact Us Now
Facebook Recovery Network
Follow Us on Twitter
Sign Up for More Info!
 
 
Become a Provider
Studies on Prometa
 
Only a physician licensed to treat with the Prometa Treatment Program can determine if they are appropriate for any individual patient. The medications used in the Prometa Treatment Program are Food and Drug Administration (FDA) approved for uses other than treating dependence on alcohol, cocaine or methamphetamine. Therefore, the risks and benefits of using these medications to treat dependence on these substances have not been evaluated by the FDA. 

The information provided herein is for general education purposes only and is not medical advice. Hythiam does not provide treatment or make treatment recommendations.Hythiam does not practice medicine or provide medical care to patients.

©2010 Hythiam, Inc. All rights reserved. The Prometa Treatment Program is proprietary, patented and patent pending. Hythiam, the Hythiam logo, Prometa®, the Prometa Treatment Program, and the Prometa logo are trademarks of Hythiam, Inc. Hythiam does not manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the Prometa Treatment Program.

Home/Family & Friends/Healthcare Professionals/Contact Us Now/Privacy Policy/Terms of Service/Photo Disclaimer